JMT101 + irinotecan

JMT101 + irinotecan is a combination therapy under investigation for the treatment of metastatic colorectal cancer (mCRC), specifically as a ≥3rd-line therapy in patients with RAS and BRAF wild-type tumors whose disease has progressed after standard treatments. JMT101 is a humanized IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), intended to inhibit tumor cell growth through EGFR blockade. Irinotecan is a chemotherapeutic small molecule that inhibits DNA topoisomerase I, preventing DNA replication and promoting cancer cell death through DNA damage. The rationale for this combination exploits the antitumor activity of EGFR inhibition alongside the cytotoxic effects of irinotecan. This combination is being evaluated in phase II clinical studies for safety and efficacy[1][3][5].

Brand names

Camptosar

Other names

CPT-11CPT11CPT 11